Advertisement

Document › Details
European Invesmtent Bank (EIB). (11/29/19). "Press Release: A European Fund to Support the Circular Bioeconomy".
![]() |
Region | EU (European Union) |
![]() |
Organisation | European Investment Bank (EIB) |
Group | EU (govt) | |
![]() |
Product | industrial biotechnology |
![]() |
Index term | ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
![]() |
Person | McDowell, Andrew (EU (govt) 201812 VP at EIB) |
Person 2 | Brandkamp, Michael (High-Tech Gründerfonds 201112 Managing Director) | |
> The European Commission and the European Investment Bank announce the selection of an Investment Advisor for the upcoming European Circular Bioeconomy Fund
> The fund aims to provide financing for innovative circular bioeconomy companies and projects in the EU and in countries associated with the Horizon 2020 programme
The European Commission and the European Investment Bank (EIB) have announced the completion of the public procurement process for the selection of an investment advisor to set up and manage the European Circular Bioeconomy Fund (ECBF). The selected investment advisor is ECBF Management GmbH and Hauck & Aufhäuser Fund Services S.A. will act as the Alternative Investment Fund Manager.
The new fund will provide access to finance – in the form of equity, debt or quasi-equity – to innovative circular bioeconomy companies and projects of various sizes. ECBF Management will raise funds from public and private investors with a target fund volume of EUR 250 million and aims for a first close in Q1 2020. A proposal for the EIB to invest up to EUR 100 million in the fund will be submitted to the EIB’s Board of Directors for approval. This investment will be backed by a guarantee from InnovFin – EU finance for Innovators, an initiative of the EIB Group and the European Commission to facilitate access to finance for innovation and research through a wide range of financing tools and advisory services.
Carlos Moedas, Commissioner for Research, Science and Innovation, said: “Sustainable bioeconomy has the potential to play a major role for the European Green Deal. It will help us reach our environmental, climate and biodiversity targets in line with the UN Sustainable Development Goals. The European Circular Bioeconomy Fund will fill the funding gaps, attracting private investments that bring bio-based innovations closer to the market.”
Andrew McDowell, EIB Vice-President responsible for agriculture and bioeconomy, said: “Using renewable biological resources to produce our goods and energy is essential to transition to a circular economy and reduce our reliance on fossil fuels. With the launch of the European Circular Bioeconomy Fund, we have reached an important milestone to ensure that groundbreaking projects in the sector get the financing they need.”
Michael Brandkamp, Head of ECBF, said: “It’s a great honour and privilege as well as an entrepreneurial obligation for us to be chosen by the EIB to execute this very important fund initiative. In the transforming industry we see great investment opportunities in Europe contributing to a sustainable circular economy. With more than 30 years of investment experience, the ECBF team has the right qualifications do the execution professionally. We are very grateful for the valuable support of the European Commission, the EIB, InnovFin, Hauck & Aufhäuser, and many other institutions and networking partners.”
The creation of such a fund was recommended by the 2017 Innovfin Advisory study Access-to-finance conditions for Investments in Bio-Based Industries and the Blue Economy which identified an important financing gap in the bioeconomy sector.
Background information
InnovFin – EU Finance for Innovators was launched, by the European Investment Bank Group (EIB and EIF) in cooperation with the European Commission under the EU Research and Innovation Framework Programme Horizon 2020. It aims to facilitate access to finance for innovation and research through a wide range of financing tools and advisory services, and secure Europe's global competitiveness.
In a transforming economy, the European Circular Bioeconomy Fund (ECBF) invests and partners with ambitious and visionary entrepreneurs to accelerate late stage companies. ECBF relies on expertise and powerful networks to catalyze sustainable innovations and fuel business growth. We aim to fill a funding gap in the European (bio-)economy, bringing Europe’s excellent expertise in circular technologies to market. ECBF will be established in Luxembourg, advised by an experienced venture capital team within ECBF Management GmbH and managed by Hauck & Aufhäuser Funds Services S.A. (AIFM). Being a market standard growth stage venture capital fund, ECBF has the additional ability to focus on project financing as well as typical venture capital investment structures. More information on the ECBF on www.ecbf.vc
Contact
Vanessa Paul
v.paul@eib.org
+352437984331
Press Office
press@eib.org
+352 4379 - 21000
Related tags
BioeconomyCircular economyInnovFin
Reference
2019-328-EN
Record changed: 2019-12-03 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for EU (govt)
- [1] Avantium N.V.. (11/28/19). "Press Release: Avantium Secures Financing Milestone with €25 million EU Funding for FDCA Flagship Plant". Amsterdam....
- [2] MaxiVax S.A.. (11/26/19). "Press Release: MaxiVax Awarded €2,785,000 European Commission Grant and Announces Successful Closing of Its Series B 2 Round for an Amount of CHF 5 Million". Geneva....
- [3] Arnold & Porter LLP. (10/22/19). "Press Release: Life Sciences Lawyer and Former EMA Legal Adviser Alexander Roussanov Joins Arnold & Porter in Brussels". Brussels....
- [4] Kiadis Pharma N.V.. (10/17/19). "Press Release: Kiadis Pharma Provides Regulatory Update on ATIR101". Amsterdam....
- [5] Univercells S.A.. (10/3/19). "Press Release: Univercells Boosted by EUR 20m European Financing to Accelerate the Delivery of Its Vaccine Portfolio". Brussels....
- [6] Max Planck Society. (9/12/19). "Press Release: Launch of Tech Transfer Fund KHAN-I"....
- [7] Roche. (8/29/19). "Press Release: European Commission Approves Roche’s Tecentriq in Combination with Abraxane for People with PD-L1-positive, Metastatic Triple-negative Breast Cancer". Basel....
- [8] RhoVac AB. (8/22/19). "Press Release: RhoVac AB Has Been Granted 2.5 Million Euro from Horizon 2020"....
- [9] Inscreenex GmbH. (7/15/19). "Press Release: Inscreenex Wins Horizon 2020 SME Instrument Phase-1 Support". Braunschweig....
- [10] Bluebird Bio, Inc.. (6/3/19). "Press Release: Bluebird Bio Announces EU Conditional Marketing Authorization for Zynteglo (autologous CD34+ cells encoding ßA-T87Q-globin gene) Gene Therapy". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top